Medicare AdvantageCoverageMedium impact
MA08.049q, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.049q establishes coverage and billing requirements for Abraxane® (paclitaxel protein-bound particles for injectable suspension) under Medicare Advantage plans effective October 1, 2025. This recent pharmacy policy requires the billing team to verify coverage criteria, prior authorization requirements, and applicable HCPCS codes for all Abraxane® claims to ensure proper reimbursement and avoid denials.
Action Required
By September 30, 2025: Billing team must review the complete MA08.049q policy text to identify specific prior authorization requirements, coverage criteria, and any quantity limits or age restrictions for Abraxane® (HCPCS J9264). Update billing system rules and claim submission processes to comply with the policy. Clinical staff should be notified of any new documentation requirements. Begin screening all Abraxane® claims submitted on or after October 1, 2025 against the policy requirements before submission to avoid denials. Oncology practices should flag this policy for provider education.